Takeda gets Japanese antitrust regulators' blessing for Shire deal; France's Acticor Biotech raises €15.3M for stroke drug
→ Takeda has cleared another hurdle for the Shire buyout that would make it one of the world’s 10 biggest pharma companies. The fair trade commission in Japan — Takeda’s ancestral home — has granted “unconditional clearance” for the acquisition, joining antitrust regulators in the US, China and Brazil. The EU has yet to give its final decision, which is expected in November. “Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,” said CEO Christophe Weber, whose globalization strategy has been meeting some high-profile pushback from traditionalists at the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.